September 8, 2017
This article originally appeared on The Advocate.
Research published in the journal JAMA Pediatrics found that the HIV prevention strategy, involving a daily dose of the drug Truvada, “can safely reduce risk for those under 18,” deduced Dr. Bill Kapogiannis, from the U.S. National Institute of Child Health Development.
The study recruited 78 gay and bisexual male participants ages 15 to 17 from six U.S. cities. About 30 percent were African-American, 21 percent were Hispanic, and 14 percent were white. The teens, who were HIV-negative when they began PrEP, were considered at high risk for infection.
At the end of the 48-week study, three participants tested positive for HIV. However, blood tests found that these participants had taken the drug less than twice a week — far less than the prescribed daily doses provided.